Articles from Lifeward Ltd.

Record quarterly and annual revenue of $7.5M and $25.7M, respectively

CorLife to become the exclusive distributor of the ReWalk Personal Exoskeleton for individuals with Workers’ Compensation claims

New Agreement Expands Distribution Rights to Lifeward to Include Referral Sales for Home Use Applications

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a  global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its fourth quarter and fiscal year-end financial results before the markets open on Friday, March 7, 2025.

CEO Larry Jasinski to Retire

Lifeward signs contractual agreement with BARMER, Germany’s second largest statutory health insurance company, to streamline access to ReWalk Personal Exoskeletons for eligible beneficiaries

MARLBOROUGH, Mass., and YOKNEAM ILLIT, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that it will host a virtual Investor Event on Thursday, February 20, 2025, beginning at 10:00 am EST. The event will feature presentations and question-and-answer sessions by members of the executive leadership team on the Company's strategy, key initiatives, and financial outlook. To register for the webcast, click here.

With recent financing and current capital, the Company believes it has sufficient cash to pursue its goals

MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), today announced that it has cancelled its previously announced Extraordinary General Meeting of Shareholders that had been scheduled for January 13, 2025. The Board of Directors of Lifeward (the “Board”) has withdrawn from consideration by the shareholders of the Company the proposals set forth in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on November 25, 2024. The Company’s Board intends to present these proposals at a subsequent meeting in 2025.

MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life’s passions in the face of physical limitation or disability, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the issuance and sale of an aggregate of 1,818,183 of the Company’s ordinary shares at a purchase price of $2.75 per share. In addition, in a concurrent private placement, the Company issued unregistered short-term warrants to purchase up to 1,818,183 of the Company’s ordinary shares. The warrants have a term of three years, are exercisable immediately following the issuance date and have an exercise price of $2.75 per share.

MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life’s passions in the face of physical limitation or disability, announced today that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,818,183 of the Company’s ordinary shares at a purchase price of $2.75 per share in a registered direct offering priced at-the-market under the rules of the Nasdaq Stock Market. In addition, in a concurrent private placement, the Company will issue unregistered short-term warrants to purchase up to 1,818,183 of the Company’s ordinary shares.  The warrants will have a term of three years, will be exercisable immediately following the issuance date and have an exercise price of $2.75 per share. The closing of the offering is expected to occur on or about January 8, 2025, subject to the satisfaction of customary closing conditions.

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life’s passions in the face of physical limitation or disability, today announced that the Company’s Extraordinary General Meeting of Shareholders (the “Meeting), which was originally scheduled to be held on Monday, December 30, 2024, has been postponed. The Meeting is now scheduled to be held at 10:00 a.m. (Eastern Standard Time) on Monday, January 13, 2025 at the Company’s offices at 200 Donald Lynch Blvd., Marlborough, MA 01752, U.S.A. The record date for the Meeting, November 20, 2024, is unchanged and applies to the postponed Meeting.

Research at the prestigious Semmelweis University, Budapest, Hungary has led the way in achieving government coverage in Hungary with a code for exoskeleton training that expands access to additional spinal cord injury centers

Second consecutive quarter of 20 ReWalk systems sold

Financial executive brings over 30 years of experience and leadership in financial management and strategy